scholarly journals Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D

2013 ◽  
Vol 88 (5) ◽  
pp. 2645-2657 ◽  
Author(s):  
A. T. McGuire ◽  
J. A. Glenn ◽  
A. Lippy ◽  
L. Stamatatos ◽  
R. W. Doms
Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1448 ◽  
Author(s):  
Aurélien Pélissier ◽  
Youcef Akrout ◽  
Katharina Jahn  ◽  
Jack Kuipers  ◽  
Ulf Klein  ◽  
...  

Germinal centers (GCs) are specialized compartments within the secondary lymphoid organs where B cells proliferate, differentiate, and mutate their antibody genes in response to the presence of foreign antigens. Through the GC lifespan, interclonal competition between B cells leads to increased affinity of the B cell receptors for antigens accompanied by a loss of clonal diversity, although the mechanisms underlying clonal dynamics are not completely understood. We present here a multi-scale quantitative model of the GC reaction that integrates an intracellular component, accounting for the genetic events that shape B cell differentiation, and an extracellular stochastic component, which accounts for the random cellular interactions within the GC. In addition, B cell receptors are represented as sequences of nucleotides that mature and diversify through somatic hypermutations. We exploit extensive experimental characterizations of the GC dynamics to parameterize our model, and visualize affinity maturation by means of evolutionary phylogenetic trees. Our explicit modeling of B cell maturation enables us to characterise the evolutionary processes and competition at the heart of the GC dynamics, and explains the emergence of clonal dominance as a result of initially small stochastic advantages in the affinity to antigen. Interestingly, a subset of the GC undergoes massive expansion of higher-affinity B cell variants (clonal bursts), leading to a loss of clonal diversity at a significantly faster rate than in GCs that do not exhibit clonal dominance. Our work contributes towards an in silico vaccine design, and has implications for the better understanding of the mechanisms underlying autoimmune disease and GC-derived lymphomas.


PLoS ONE ◽  
2015 ◽  
Vol 10 (7) ◽  
pp. e0132571 ◽  
Author(s):  
Lenka Plzakova ◽  
Zuzana Krocova ◽  
Klara Kubelkova ◽  
Ales Macela

Immunity ◽  
2008 ◽  
Vol 29 (6) ◽  
pp. 912-921 ◽  
Author(s):  
Fabian Köhler ◽  
Eva Hug ◽  
Cathrin Eschbach ◽  
Sonja Meixlsperger ◽  
Elias Hobeika ◽  
...  

2000 ◽  
Vol 175 (1) ◽  
pp. 33-46 ◽  
Author(s):  
Fritz Melchers ◽  
Edwin ten Boekel ◽  
Thomas Seidl ◽  
Xian Chu Kong ◽  
Tamotsu Yamagami ◽  
...  

Immunology ◽  
1996 ◽  
Vol 88 (4) ◽  
pp. 593-599 ◽  
Author(s):  
T. NAKAMURA ◽  
M. KOYAMA ◽  
A. YONEYAMA ◽  
M. HIGASHIHARA ◽  
T. KAWAKAMI ◽  
...  

2018 ◽  
Author(s):  
Pia Dosenovic ◽  
Ervin E. Kara ◽  
Anna-Klara Pettersson ◽  
Andrew McGuire ◽  
Matthew Gray ◽  
...  

AbstractThe discovery that humans can produce potent broadly neutralizing antibodies (bNAbs) to several different epitopes on the HIV-1 spike has reinvigorated efforts to develop an antibody based HIV-1 vaccine. Antibody cloning from single cells revealed that nearly all bNAbs show unusual features that could help explain why it has not been possible to elicit them by traditional vaccination, and instead that it would require a sequence of different immunogens. This idea is supported by experiments with genetically modified immunoglobulin knock-in mice. Sequential immunization with a series of specifically designed immunogens was required to shepherd the development of bNAbs. However, knock-in mice contain super-physiologic numbers of bNAb precursor expressing B cells and therefore how these results can be translated to a more physiologic setting remains to be determined. Here we make use of adoptive transfer experiments using knock-in B cells that carry a synthetic intermediate in the pathway to anti-HIV-1 bNAb development to examine how the relationship between B cell receptor affinity and precursor frequency affects germinal center B cell recrutiment and clonal expansion. Immunization with soluble HIV-1 antigens can recruit bNAb precursor B cells to the germinal center when there are as few as 10 such cells per mouse. However, at low precursor frequencies the extent of clonal expansion is directly proportional to the affinity of the antigen for the B cell receptor, and recruitment to germinal centers is variable and dependent on re-circulation.Significance statementAn essential requirement for an HIV-vaccine is to elicit antibodies to conserved regions of the spike protein (Env) becasue these antibodies can protect against infection. Although broadly neutralizing antibodies develop naturally in rare individuals after prolongued HIV infection, eliciting them by vaccination has only been possible in artificial knock-in mouse models wherein the number of B cells expressing the antibody precursor is super-physiologic. To understand the relationship between precursor frequency, antigen affinity and germinal center recruitment we have performed adoptive transfer experiments in which fixed numbers of precursor cells are engrafted in wild type mice. Our results provide a framework for understanding how precursor frequency and antigen affinity shape humoral immunity to HIV.


2019 ◽  
Author(s):  
Theresa Pesch ◽  
Lucia Bonati ◽  
William Kelton ◽  
Cristina Parola ◽  
Roy A Ehling ◽  
...  

AbstractImmune cell therapies based on the integration of synthetic antigen receptors provide a powerful strategy for the treatment of diverse diseases, most notably retargeting T cells engineered to express chimeric antigen receptors (CAR) for cancer therapy. In addition to T lymphocytes, B lymphocytes may also represent valuable immune cells that can be engineered for therapeutic purposes such as protein replacement therapy or recombinant antibody production. In this article, we report a promising concept for the molecular design, optimization and genomic integration of a novel class of synthetic antigen receptors, chimeric B cell receptors (CBCR). We initially optimized CBCR expression and detection by modifying the extracellular surface tag, the transmembrane regions and intracellular signaling domains. For this purpose, we stably integrated a series of CBCR variants into immortalized B cell hybridomas using CRISPR-Cas9. Subsequently, we developed a reliable and consistent pipeline to precisely introduce cassettes of several kilobases size into the genome of primary murine B cells, again via CRISPR-Cas9 induced HDR. Finally, we were able to show the robust surface expression and antigen recognition of a synthetic CBCR in primary B cells. We anticipate that CBCRs and our approach for engineering primary B cells will be a valuable tool for the advancement of future B cell-based immune therapies.


Sign in / Sign up

Export Citation Format

Share Document